‘Invest in BC’ is Organized by LifeSciences BC
November 01, 2023 | Vancouver, British Columbia | Public Announcement – SnapCyte Solutions Inc. CTO, Dr. Negin Farivar, is presenting at the LifeSciences BC event: Invest in BC held at the Terminal City Club on November 2, 2023. This is an opportunity to demonstrate to BC investors the technology and innovation of SnapCyte’s pipeline.
“We look forward to presenting the innovative technology that we have developed to generate AI-based cell analysis tools to the investors at Invest in BC. We recently launched the SnapCyte™ Cell Confluency App and Adapter (August 2023) and are now training the algorithm further to support other projects in our pipeline. We’re expanding our tech with a cell counting feature, set to hit the market in early 2024. Invest in BC will be a great opportunity for us to share our journey so far and showcase our roadmap towards a state-of-the-art and all in one cell analytics toolbox,” says Dr. Negin Farivar, CTO and co-founder of SnapCyte Solutions Inc.
About SnapCyte Solutions Inc.
SnapCyte Solutions Inc. is a privately held company incorporated in British Columbia, Canada. The company develops and distributes AI-based smartphone applications for assessment of cell culture growth and fitness in the biology and life science research fields. The company also develops and distributes microscope adapters for mounting smartphones to microscopes.
About Invest in BC
The LifeSciences BC: Invest in BC-event serves as a premier gathering for healthcare innovators in British Columbia, connecting them with global investors. Entrepreneurs participating in this exclusive event gain an invaluable platform to share their stories, receive actionable feedback, and establish connections with diverse stakeholders. These stakeholders include angel investors, venture capitalists, corporate venture firms, and foundations, creating opportunities for collaboration and growth.
Confirmed investors: Accelerator Life Science Partners; Adelante Capital; adMare BioInnovations; AioT Health; AllosteRx Capital; Amplitude Ventures; Bausch Health; Biogen Canada; CQDM; CTI Life Sciences Fund; CVM; eFund; entrepreneurship@UBC; Genome BC; J.P. Morgan; Johnson & Johnson; Lumira Ventures; Merck; Moderna; Nimbus Synergies; Nodes Advisors AG; Providence Health Care Ventures; Quark Venture; Rising Tide; Roche; Sanofi; Taiho Ventures, LLC; United Therapeutics; Versant Ventures.
